BI-D1870

CAT: 0804-HY-10510-01Size: 2 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10510-01Size:2 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
BI-D1870 is an ATP-competitive, cell permeable and brain penetrated inhibitor of RSK isoforms, with IC50s of 31 nM/24 nM/18 nM/15 nM for RSK1/RSK2/RSK3/RSK4, respectively[1][2][3][4][5].
CAS Number
[501437-28-1]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; Ribosomal S6 Kinase (RSK)
Type
Reference compound
Related Pathways
Autophagy; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BI-D1870.html
Purity
99.43
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC1=C(F)C=C(NC2=NC(N(CCC(C)C)C(C)C(N3C)=O)=C3C=N2)C=C1F
Molecular Formula
C19H23F2N5O2
Molecular Weight
391.42
Precautions
H302, H315, H319, H335
References & Citations
[1]Sapkota GP, et al. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007 Jan 1;401 (1) :29-38.|[2]Ciceri P, et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol. 2014 Mar 2.|[3]Takada I, et al. The ribosomal S6 kinase inhibitor BI-D1870 ameliorated experimental autoimmune encephalomyelitis in mice. Immunobiology. 2016 Feb;221 (2) :188-92.|[4]Roffe M, et al. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner. Cell Signal. 2015 Aug;27 (8) :1630-42.|[5]Chiu CF, et al. Antitumor effects of BI-D1870 on human oral squamous cell carcinoma. Cancer Chemother Pharmacol. 2014 Feb;73 (2) :237-47.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products